Hereditary ovarian cancer


Cite item

Full Text

Abstract

Epithelial carcinoma or ovarian cancer (OC) is the fifth most common cause of cancer mortality in women, and hereditary/familial OC occurs in 15-20% of all cases. Approximately 1/2 of these cases are developed due to germline mutations in the BRCA1/BRCA2 genes. OC associated with BRCA1/BRCA2 mutations are highly sensitive to platinum based chemotherapy regimens and to chemotherapy with the inclusion of targeted drugs. BRCA1 and BRCA2 mutations are multivarious, but they lead to one result: the synthesis of defective protein which is unable to participate in homologous recombination or damaged DNA reparation. There is an interesting fact that the large variety of mutations can be found in different ethnic populations. The Slavic Russian population is characterized by a "founder effect" in BRCA1 gene, especially in case of hereditary breast cancer. However, OC has its special characteristics as in the distribution of frequency BRCA1 mutations and occasional BRCA2 mutations, and in the incidence rate of somatic mutations in the same genes. This phenomenon requires special approach in case of choice of population, material for mutations testing and in choosing the most appropriate research methodology.

About the authors

I A Demidova

Moscow City Oncology Hospital №62

Email: dema-80@yandex.ru
канд. мед. наук, зав. молекулярно-биологической лаб. ГАУЗ МГОБ №62 143423, Russian Federation, town Istra, d. 27

References

  1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin 2010; 60: 277-300.
  2. Ovarian cancer, five - year stage - specific relative survival rates (2004- 2008). J Natl Cancer Inst 2011; 103: 1287.
  3. Rubin S.C, Benjamin I, Behbakht K et al. Clinical and pathological features of ovarian cancer in women with germ - line mutations of BRCA1. N Eng J Med 1996; 335: 1413-6.
  4. Sun Ch, Li N, Weng D et al. The Role of BRCA Status on the Prognosis of Patients with Epithelial Ovarian Cancer: A Systematic Review of the Literature with a Meta-Analysis. PLOS ONE 2014; 9 (5): e95285.
  5. Bhattacharyya A, Ear U.S, Koller B.H et al. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross - linking agent cisplatin. J Biol Chem 2000; 275: 23899-903.
  6. Davies A.A, Masson J.Y, Mc Ilwraith M.J et al. Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol Cell 2000; 7: 273-82.
  7. Kowalczykowski S.C. Molecular mimicry connects BRCA2 to Rad51 and recombinational DNA repair. Nat Struct Biol 2002; 9: 897-9.
  8. Audeh M.W, Carmichael J, Penson R.T et al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof - of - concept trial. Lancet 2010; 376: 245-51.
  9. Fong P.C, Boss D.S, Yap T.A et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-34.
  10. Honrado E, Benítez J, Palacios J. The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Mod Pathol 2005; 18 (10): 1305-20.
  11. Lynch H.T, Snyder C.L, Lynch J.F et al. Family information service participation increases the rates of mutation testing among members of families with BRCA1/2 mutations. Breast J 2009; 15 (Suppl. 1): S20-4.
  12. Zhang J. The role of BRCA1 in homologous recombination repair in response to replication stress: significance in tumorigenesis and cancer therapy. Cell Biosci 2013; 3 (1): 11.
  13. Maxwell C.A, Benítez J, Gómez-Baldó L et al. Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biol 2011; 9 (11): e1001199.
  14. Li D, Ilnytskyy Y, Kovalchuk A et al. Crucial role for early growth response-1 in the transcriptional regulation of miR-20b in breast cancer. Oncotarget 2013; 4 (9): 1373-87.
  15. Welcsh P.L, King M.C. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer, Human Mol Gen 2001; 10 (7): 705-13.
  16. Foulkes W.D, Shuen A.Y. In brief: BRCA1 and BRCA2 J Pathol 2013; 230 (4): 347-9.
  17. Jacobs I.J, Kohler M.F, Wiseman R.W et al. Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation J Nat Cancer Inst 1992; 84 (23): 1793-8.
  18. Hilton J.L, Geisler J.P, Rathe J.A et al. Inactivation of BRCA1 and BRCA2 in ovarian cancer (2002) J Nat Cancer Inst 2002; 94 (18): 1396-406.
  19. Mavaddat N, Barrowdale D, Andrulis IL et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: Results from the consortium of investigators of modifiers of BRCA1/2 (CIMBA). Cancer Epid Biomarkers Prevent 2012; 21 (1): 134-47.
  20. Levy-Lahad E, Catane R, Eisenberg S et al. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast - ovarian cancer families. Am J Hum Genet 1997; 60 (5): 1059-67.
  21. Johannesdottir G, Gudmundsson J, Bergthorsson J.T et al. High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients. Cancer Res 1996; 56: 3663-5.
  22. Hamel N, Feng B.J, Foretova L et al. On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations. Eur J Hum Genet 2011; 19 (3): 300-6.
  23. Любченко Л.Н. Наследственный рак молочной̆ железы и/или яичников: ДНК-диагностика, индивидуальный̆ прогноз, лечение и профилактика. Автореф. дис. … д - ра мед. наук. М., 2009.
  24. Sokolenko A.P, Mitiushkina N.V, Buslov K.G et al. High frequency of BRCA1 5382insC mutation in Russian breast cancer patients. Eur J Cancer 2006; 42 (10): 1380-4.
  25. Suspitsin E.N, Sherina N.Y, Ponomariova D.N et al. High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients. Hered Cancer Clin Pract 2009; 7 (1): 5.
  26. Ratajska M, Krygier M, Stukan M et al. Mutational analysis of BRCA1/2 in a group of 134 consecutive ovarian cancer patients. Novel and recurrent BRCA1/2 alterations detected by next generation sequencing. J Appl Genet 2015; 56 (2): 193-8.
  27. Górski B, Jakubowska A, Huzarski T et al. A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer 2004; 110 (5): 683-6.
  28. Foster K.A, Harrington P, Kerr J et al. Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer. Cancer Res 1996; 56 (16): 3622-5.
  29. Berchuck A, Heron K.A, Carney M.E et al. Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res 1998; 4 (10): 2433-7.
  30. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474 (7353): 609-15.
  31. Alsop K, Fereday S, Meldrum C et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation - positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 2012; 30 (21): 2654-63.
  32. Ready K, Gutierrez-Barrera A.M, Amos C et al. Cancer risk management decisions of women with BRCA1 or BRCA2 variants of uncertain significance. Breast J 2011; 17 (2): 210-2.
  33. Ratajska M, Brozek I, Senkus-Konefka E et al. BRCA1 and BRCA2 point mutations and large rearrangements in breast and ovarian cancer families in Northern Poland. Oncol Rep 2008; 19 (1): 263-8.
  34. Rudnicka H, Debniak T, Cybulski C et al. Large BRCA1 and BRCA2 genomic rearrangements in Polish high - risk breast and ovarian cancer families. Mol Biol Rep 2013; 40 (12): 6619-23.

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies